H.U. Group Holdings (4544) Fundamentals 2026 — P/E 27.2x, Revenue Analysis | SniperIQ
H.U. Group Holdings (4544) is a JP-listed Healthcare company in Medical - Diagnostics & Research with a market capitalization of ¥185.5B, trading at ¥3344.00 on the JPX. This SniperIQ fundamentals page covers H.U. Group Holdings's valuation (P/E 27.2x, P/B 1.3x), profitability (net margin 2.8%), revenue (¥247.4B in FY2026), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is H.U. Group Holdings's market cap?
H.U. Group Holdings (4544) has a market capitalization of approximately ¥185.5B, trading at ¥3344.00 on the JPX. Market cap moves with the live share price.
What is H.U. Group Holdings's P/E ratio?
H.U. Group Holdings's trailing twelve-month P/E ratio is 27.2x, with a price-to-book (P/B) of 1.3x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is H.U. Group Holdings?
H.U. Group Holdings runs a net profit margin of 2.8%, a gross margin of 28.8%, and an operating margin of 1.9%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does H.U. Group Holdings generate?
H.U. Group Holdings reported revenue of ¥247.4B for fiscal year 2026, with net income of ¥6.8B and earnings per share (EPS) of 121.51. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does H.U. Group Holdings pay a dividend?
H.U. Group Holdings offers a trailing dividend yield of about 3.7%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is H.U. Group Holdings financially healthy?
H.U. Group Holdings carries a debt-to-equity ratio of 0.54x and a current ratio of 1.72x, with a market beta of 0.29. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is H.U. Group Holdings a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For H.U. Group Holdings (4544) the key facts are: market cap ¥185.5B, P/E 27.2x, revenue ¥247.4B, 52-week range 2944.5-4093. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track H.U. Group Holdings's full fundamentals live
Get H.U. Group Holdings's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.